Table of contents
Volume 94, Issue 9
Published online 2 May 2006 (1217-1354)
Clinical Studies |
Translational Therapeutics |
Molecular Diagnostics |
Epidemiology |
Letters to the Editor |
Corrigendum
Minireviews
The place of VEGF inhibition in the current management of renal cell carcinoma FREE
P Nathan, D Chao, C Brock, P Savage, M Harries, M Gore and T Eisen for the London Biological and Targeted Therapy Group
Br J Cancer 94: 1217-1220; advance online publication, February 28, 2006; doi:10.1038/sj.bjc.6603025
Adiponectin and cancer: a systematic review FREE
I Kelesidis, T Kelesidis and C S Mantzoros
Br J Cancer 94: 1221-1225; advance online publication, March 28, 2006; doi:10.1038/sj.bjc.6603051
Clinical Studies
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy FREE
M E de Jonge, A D R Huitema, J H Beijnen and S Rodenhuis
Br J Cancer 94: 1226-1230; advance online publication, April 18, 2006; doi:10.1038/sj.bjc.6603097
Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumours FREE
C Ackers and G J S Rustin
Br J Cancer 94: 1231-1232; advance online publication, April 11, 2006; doi:10.1038/sj.bjc.6603087
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial FREE
C Pacilio, A Morabito, F Nuzzo, A Gravina, V Labonia, G Landi, E Rossi, E De Maio, M Di Maio, G D'aiuto, G Botti, N Normanno, P Chiodini, C Gallo, F Perrone and A de Matteis on behalf of the NCI-Naples Breast Cancer Group
Br J Cancer 94: 1233-1236; advance online publication, April 18, 2006; doi:10.1038/sj.bjc.6603096
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer FREE
S Kümmel, J Krocker, A Kohls, G-P Breitbach, G Morack, M Budner, J-U Blohmer and D Elling
Br J Cancer 94: 1237-1244; advance online publication, April 11, 2006; doi:10.1038/sj.bjc.6603085
Baseline psychosocial predictors of survival in localised breast cancer FREE
U-S Lehto, M Ojanen, T Dyba, A Aromaa and P Kellokumpu-Lehtinen
Br J Cancer 94: 1245-1252; doi:10.1038/sj.bjc.6603091
Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors FREE
N M Gray, L Sharp, S C Cotton, L F Masson, J Little, L G Walker, M Avis, Z Philips, I Russell, D Whynes, M Cruickshank and C M Woolley on behalf of the TOMBOLA group
Br J Cancer 94: 1253-1262; advance online publication, April 4, 2006; doi:10.1038/sj.bjc.6603086
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study FREE
C Tibaldi, T Prochilo, F Russo, M C Pennucci, A Del Freo, F Innocenti, A Fabbri, A Falcone, P F Conte and E Baldini
Br J Cancer 94: 1263-1266; advance online publication, April 4, 2006; doi:10.1038/sj.bjc.6603074
Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer FREE
A Kinoshita, M Fukuda, H Soda, S Nagashima, M Fukuda, H Takatani, M Kuba, Y Nakamura, J Tsurutani, S Kohno and M Oka for the Nagasaki Thoracic Oncology Group (NTOG)
Br J Cancer 94: 1267-1271; advance online publication, April 4, 2006; doi:10.1038/sj.bjc.6603079
Systematic review of factors influencing patient and practitioner delay in diagnosis of upper gastrointestinal cancer FREE
S Macdonald, U Macleod, N C Campbell, D Weller and E Mitchell
Br J Cancer 94: 1272-1280; advance online publication, April 11, 2006; doi:10.1038/sj.bjc.6603089
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma FREE
M E Burge, D Smith, C Topham, D P Jackson, D A Anthoney, F Halstead and M T Seymour
Br J Cancer 94: 1281-1286; advance online publication, April 11, 2006; doi:10.1038/sj.bjc.6603084
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients FREE
M Mabro, P Artru, T André, M Flesch, F Maindrault-Goebel, B Landi, G Lledo, A Plantade, C Louvet and A de Gramont on behalf of GERCOR
Br J Cancer 94: 1287-1292; advance online publication, April 11, 2006; doi:10.1038/sj.bjc.6603095
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer FREE
U Graeven, B Kremer, Th Südhoff, B Killing, F Rojo, D Weber, J Tillner, C Ünal and W Schmiegel
Br J Cancer 94: 1293-1299; advance online publication, April 4, 2006; doi:10.1038/sj.bjc.6603083
Translational Therapeutics
RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells FREE
A Strillacci, C Griffoni, E Spisni, M C Manara and V Tomasi
Br J Cancer 94: 1300-1310; advance online publication, April 11, 2006; doi:10.1038/sj.bjc.6603094
The 
2
1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines FREE
J J Grzesiak and M Bouvet
Br J Cancer 94: 1311-1319; advance online publication, April 4, 2006; doi:10.1038/sj.bjc.6603088
Molecular Diagnostics
Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival FREE
A M Hanly, M Redmond, D C Winter, S Brophy, J M Deasy, D J Bouchier-Hayes and E W Kay
Br J Cancer 94: 1320-1325; advance online publication, April 18, 2006; doi:10.1038/sj.bjc.6603098
Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition FREE
D Krubasik, N G Iyer, W R English, A A Ahmed, M Vias, C Roskelley, J D Brenton, C Caldas and G Murphy
Br J Cancer 94: 1326-1332; advance online publication, April 18, 2006; doi:10.1038/sj.bjc.6603101
Oestrogen receptor and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment FREE
W R Miller, T J Anderson, J M Dixon and P T K Saunders
Br J Cancer 94: 1333-1338; advance online publication, April 18, 2006; doi:10.1038/sj.bjc.6603082
Epidemiology
Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish Population-based Cohort Study FREE
M Nørgaard, A H Poulsen, L Pedersen, H Gregersen, S Friis, M Ewertz, H E Johnsen and H T Sørensen
Br J Cancer 94: 1339-1341; doi:10.1038/sj.bjc.6603123
Childhood leukaemia incidence around French nuclear installations using geographic zoning based on gaseous discharge dose estimates FREE
A-S Evrard, D Hémon, A Morin, D Laurier, M Tirmarche, J-C Backe, M Chartier and J Clavel
Br J Cancer 94: 1342-1347; advance online publication, April 18, 2006; doi:10.1038/sj.bjc.6603111
Letters to the Editor
Mobile phone use and risk of acoustic neuroma: results of the interphone case–control study in five North European countries FREE
L Hardell and K Hansson Mild
Br J Cancer 94: 1348-1349; advance online publication, March 28, 2006; doi:10.1038/sj.bjc.6603070
Mobile phone use and risk of acoustic neuroma FREE
B Hocking
Br J Cancer 94: 1350; advance online publication, March 28, 2006; doi:10.1038/sj.bjc.6603069
Mobile phone use and risk of glioma in adults: case–control study FREE
S Milham
Br J Cancer 94: 1351; advance online publication, March 28, 2006; doi:10.1038/sj.bjc.6603068
Reply: Mobile phone use and acoustic neuroma in five North European countries FREE
M J Schoemaker, A J Swerdlow, A Auvinen, E Cardis, M Feychting, C Johansen, P A McKinney and T Tynes
Br J Cancer 94: 1352-1353; advance online publication, March 28, 2006; doi:10.1038/sj.bjc.6603071
Corrigendum
Mobile phone use and risk of glioma in adults: case–control study FREE
S Milham
Br J Cancer 94: 1354; doi:10.1038/sj.bjc.6603128
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
